%0 Generic %A G.B., Thoennissen %A D., Görlich %A U., Bacher %A T., Aufenberg %A A.-C., Hüsken %A A.A., Hansmeier %A G., Evers %A J.-H., Mikesch %A F., Fritz %A C., Bokemeyer %A C., Müller-Tidow %A M., Stelljes %A R.M., Mesters %A U., Krug %A M.H., Kropff %A N.H., Thoennissen %A W.E., Berdel %D 2017 %T Supplementary Material for: Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Autologous_Stem_Cell_Transplantation_in_Multiple_Myeloma_in_the_Era_of_Novel_Drug_Induction_A_Retrospective_Single-Center_Analysis/4859606 %R 10.6084/m9.figshare.4859606.v1 %2 https://karger.figshare.com/ndownloader/files/8053421 %2 https://karger.figshare.com/ndownloader/files/8053430 %2 https://karger.figshare.com/ndownloader/files/8053439 %K Autologous stem cell transplantation %K Induction therapy %K Melphalan high-dose chemotherapy %K Multiple myeloma %K Novel compounds %K Tandem autologous stem cell transplantation %X

Within this retrospective single-center study, we analyzed the survival of 320 multiple myeloma (MM) patients receiving melphalan high-dose chemotherapy (HDCT) and either single (n = 286) or tandem (n = 34) autologous stem cell transplantation (ASCT) from 1996 to 2012. Additionally, the impact of novel induction regimens was assessed. Median follow-up was 67 months, median overall survival (OS) 62 months, median progression-free survival (PFS) 33 months (95% CI 27-39), and treatment-related death (TRD) 3%. Multivariate analysis revealed age ≥60 years (p = 0.03) and stage 3 according to the International Staging System (p = 0.006) as adverse risk factors regarding PFS. Median OS was significantly better in newly diagnosed MM patients receiving induction therapy with novel agents, e.g., bortezomib, thalidomide, or lenalidomide, compared with a traditional regimen (69 vs. 58 months; p = 0.01). More patients achieved at least a very good partial remission in the period from 2005 to 2012 than from 1996 to 2004 (65 vs. 30%; p < 0.001), with a longer median OS in the later period (71 vs. 52 months, p = 0.027). In conclusion, our analysis confirms HDCT-ASCT as an effective therapeutic strategy in an unselected large myeloma patient cohort with a low TRD rate and improved prognosis due to novel induction strategies.

%I Karger Publishers